---
search:
  boost: 3
---

# Atypical Antipsychotics

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [CNS - Atypical Antipsychotics - Non-Preferred- Aripiprazole Sol, Asenapine, Caplyta, Clozapine ODT Rapdis, Lurasidone, Olanzapine ODT, Paliperidone, Rexulti, Secuado, Versacloz, Vraylar](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMzYwVjA5NVhMMEtCQlFRR05CNUs0QldLWiQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Atypical Antipsychotics - Abilify Mycite](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMTE5Q01HTVBJNzFVQlRWVlZPRUFBMEE5NyQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Atypical Antipsychotics -Fluoxetine/Olanzapine](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMURVR0dISVBVSFhOUDM4UDdSNFROR1U3OSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Atypical Antipsychotics - Invega Hafyera](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNU0wVThMU1A2RUFUVjRLRlBLNkpNMkNVTiQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Atypical Antipsychotics - Lybalvi](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNEpCUFJXQ1lLQkczWDI5Vk9BMzNWRUdJMCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Atypical Antipsychotics - Nuplazid](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNkhEUkUwRzlRTVJUOE5SVzc5SU5CVEVHWSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Atypical Antipsychotics - Step Therapy Products](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQTZNWVlDN05YTFc1REtTMUs4VjgxUkVXVCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Atypical Antipsychotics - Zyprexa Relprevv](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURUMxV09QUEI2REhWTEhUQkExRUY5Q01PRiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                       | Generic Name                                                         |         Quantity          |        Time (Days)        |
|:--------------------------------|:---------------------------------------------------------------------|:-------------------------:|:-------------------------:|
| Abilify Maintena <sup>QL</sup>  | Aripiprazole ER Susp IM Inj (all strengths & formulations)           |             3             |            84             |
| Aripiprazole <sup>QL</sup>      | Aripiprazole Tab (all strengths)                                     |            102            |            102            |
| Aristada <sup>QL</sup>          | Aripiprazole Lauroxil ER Susp IM 441 MG / 1.6 ML (all formulations)  |            4.8            |            84             |
| Aristada <sup>QL</sup>          | Aripiprazole Lauroxil ER Susp IM 662 MG / 2.4 ML (all formulations)  |            7.2            |            84             |
| Aristada <sup>QL</sup>          | Aripiprazole Lauroxil ER Susp IM 882 MG / 3.2 ML (all formulations)  |            9.6            |            84             |
| Aristada <sup>QL</sup>          | Aripiprazole Lauroxil ER Susp IM 1064 MG / 3.9 ML (all formulations) |            7.8            |            102            |
| Aristada Initio                 |                                                                      |                           |                           |
| Clozapine                       |                                                                      |                           |                           |
| Fanapt <sup>ST</sup>            |                                                                      |                           |                           |
| Geodon <sup>QL</sup>            | Ziprasidone HCI Cap (all strengths)                                  |            204            |            102            |
| Invega Hafyera ER <sup>PA</sup> |                                                                      |                           |                           |
| Invega Sustenna <sup>QL</sup>   | Paliperidone Palmitate ER Susp 39 MG / 0.25 ML (all formulations)    |           0.75            |            84             |
| Invega Sustenna <sup>QL</sup>   | Paliperidone Palmitate ER Susp 78 MG / 0.5 ML (all formulations)     |            1.5            |            84             |
| Invega Sustenna <sup>QL</sup>   | Paliperidone Palmitate ER Susp 117 MG / 0.75 ML (all formulations)   |             9             |            84             |
| Invega Sustenna <sup>QL</sup>   | Paliperidone Palmitate ER Susp 156 MG / ML (all formulations)        |             6             |            84             |
| Invega Sustenna <sup>QL</sup>   | Paliperidone Palmitate ER Susp 234 MG / 1.5 ML (all formulations)    |            4.5            |            84             |
| Invega Trinza <sup>QL</sup>     | Paliperidone Palmitate ER Susp 273 MG / 0.88 ML (all formulations)   |           0.88            |            84             |
| Invega Trinza <sup>QL</sup>     | Paliperidone Palmitate ER Susp 410 MG / 1.32 ML (all formulations)   |           1.32            |            84             |
| Invega Trinza <sup>QL</sup>     | Paliperidone Palmitate ER Susp 546 MG / 1.75 ML (all formulations)   |           1.75            |            84             |
| Invega Trinza <sup>QL</sup>     | Paliperidone Palmitate ER Susp 819 MG / 2.63 ML (all formulations)   |           2.63            |            84             |
| Lurasidone <sup>QL</sup>        |                                                                      |                           |                           |
| Olanzapine <sup>QL</sup>        | Olanzapine Tab (all strengths)                                       |            102            |            102            |
| Perseris                        |                                                                      |                           |                           |
| Quetiapine IR <sup>QL</sup>     | Quetiapine Fumarate Tab 25 MG & 50 MG & 100 MG                       |            306            |            102            |
| Quetiapine IR <sup>QL</sup>     | Quetiapine Fumarate Tab 200 MG                                       |            408            |            102            |
| Quetiapine IR <sup>QL</sup>     | Quetiapine Fumarate Tab 300 MG & 400 MG                              |            204            |            102            |
| Quetiapine ER <sup>QL</sup>     | Quetiapine Fumarate ER Tab (all strengths excl 150 MG & 200 MG)      |            204            |            102            |
| Quetiapine ER <sup>QL</sup>     | Quetiapine Fumarate ER Tab 150 MG & 200 MG                           |            102            |            102            |
| Risperdal Consta <sup>QL</sup>  | Risperidone Microspheres ER IM Inj (all strengths)                   |             7             |            98             |
| Risperidone <sup>QL</sup>       | Risperidone Soln (all strengths)                                     |            816            |            102            |
| Risperidone <sup>QL</sup>       | Risperidone Tab (all strengths)                                      |            306            |            102            |
| Risperidone <sup>QL</sup>       | Risperidone ODT (all strengths)                                      |            204            |            102            |
| Saphris <sup>BvG ST ==(Process by NDC)==</sup>       |                                                                      |                           |                           |
| Paliperidone Tab                |                                                                      |                           |                           |
| Ziprasidone <sup>QL</sup>       | Ziprasidone HCI Cap (all strengths)                                  |            68             |            34             |

### Non-Preferred

| Non-Preferred                                                                              | Generic Name                                               | Quantity | Time (Days) |
|:-------------------------------------------------------------------------------------------|:-----------------------------------------------------------|:--------:|:-----------:|
| Abilify Mycite                                                                             | Aripiprazole ER Susp IM Inj (all strengths & formulations) |    3     |     84      |
| Aripiprazole Sol                                                                           |                                                            |          |             |
| <span title = "Brand Preferred: Saphris">Asenapine</span> <sup>Brand Preferred</sup>       |                                                            |          |             |
| Caplyta                                                                                    |                                                            |          |             |
| Clozapine ODT Rapdis                                                                       |                                                            |          |             |
| Fluoxetine/Olanzapine                                                                      |                                                            |          |             |
| Lybalvi                                                                                    |                                                            |          |             |
| Nuplazid                                                                                   |                                                            |          |             |
| Olanzapine ODT                                                                             |                                                            |          |             |
| Rexulti                                                                                    |                                                            |          |             |
| Secuado                                                                                    |                                                            |          |             |
| Versacloz                                                                                  |                                                            |          |             |
| Vraylar <sup>[**Vraylar for MDD Guidance](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Medication%20Guidance/vraylar/?h=vray)</sup>                                                                                   |                                                            |          |             |
| Zyprexa Relprevv <sup>QL</sup>                                                             | Olanzapine Pamoate ER Susp IM 210 MG (all formulations)    |    7     |     98      |
| Zyprexa Relprevv <sup>QL</sup>                                                             | Olanzapine Pamoate ER Susp IM 300 MG (all formulations)    |    6     |     84      |
| Zyprexa Relprevv <sup>QL</sup>                                                             | Olanzapine Pamoate ER Susp IM 405 MG (all formulations)    |    3     |     84      |

## Authorizations

**Length of Authorizations**: 365 Days

### Grandfathering*

Patients who have a claim for a non-preferred drug, or drug requiring step therapy, in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug in the previously, but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

### Psychiatrist Exemption

Providers (as identified below) are exempt from prior authorization of any non-preferred second-generation antipsychotic, 
or step therapy of any preferred drug, in the standard tablet/capsule and long-acting injectable dosage forms. 
Other dosage forms may still require prior authorization. The exemption will be processed by the claims system when the pharmacy
has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the prescriber.

Prescribers are defined as:</br>
Physicians with a specialty in psychiatry, nurse practitioners certified in psychiatric mental health,
or clinical nurse specialists certified in psychiatric mental health, who are credentialed with the Ohio Department of Medicaid.

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Paliperidone Palmitate (Invega Hafyera)

Paliperidone Palmitate (Invega Hafyera) Criteria

- Must have had 4 months of treatment with Invega Sustenna or 3 months with Invega Trinza

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^one preferred^^ drug

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^two preferred^^ drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Aripiprazole (Abilify Mycite)

Additional Aripiprazole (Abilify Mycite) Criteria

- Must be prescribed by or in consultation with a psychiatrist following an aripiprazole serum blood level draw indicating need for further investigation of adherence

### Olanzapine/Samidorphan (Lybalvi)

Additonal Olanzapine/Samidorphan (Lybalvi) Criteria

-  Must provide documentation that patient is not using opioids or undergoing acute opioid withdrawal

### Pimavanserin (Nuplazid)

Additional Pimavanserin (Nuplazid) Criteria

- For Parkinson-related Hallucinations & Delusions **ALL** of the following must be met:
    - Psychotic symptoms are severe and frequent enough to warrant treatment with an antipsychotic **AND** are not related to dementia or delirium
    - The patient’s other Parkinson’s Disease drugs have been reduced or adjusted and psychotic symptoms persist **OR** patient is unable to tolerate adjustment of these other drugs
    - Must have been inadequate clinical response or contraindication to at least ^^30 days^^ of either quetiapine or clozapine
- An exemption to the criteria will be authorized for prescribers with a neurology specialty to a patient with a history of the related condition

### Fluoxetine/Olanzapine (Symbyax)

Additional Fluoxetine/Olanzapine (Symbyax) Criteria

- Must provide documentation for patient’s inability to use the individual drugs

### Additional Information

- Long-acting injectable antipsychotics may be billed by the pharmacy if they are not dispensed directly to the patient. If not administered by the pharmacist, the drug must be released only to the administering provider or administering provider’s staff, following all regulations for a Prescription Pick-Up Station as described by the Ohio Board of Pharmacy

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=29&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} </br>
[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001+UPDL+Criteria+_v2.FINAL.pdf#page=36){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=16){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
